Limitations Associated With Use of Allografts and Autografts to Bring Orthobiologics at Forefront

Orthobiology is a branch of science that develops bone and tissue replacement materials for fasthealing and quick recovery of injured muscles, broken bones, ligaments and tendons. Orthobiologics is considered as a highly lucrative market owing to significant growth opportunities. One of the major driver for the growth of this industry is certain limitations that are associated with autografts and allografts. Although, autografts are considered as gold standard for orthopedic procedures but the usage of autograft involves donor site morbidity and an additional surgery. While, the major concerns associated with allografts is risk of disease transmission along with the decline in theiravailability. Therefore, in order to overcome these drawbacks of the autografts and allografts, bone graft substitutes are being preferred for use in orthopaedic surgery.

According to the American Academy of Orthopedic Surgeons (AAOS), approximately 465,000 spinal surgeries were performed in the U.S in 2011. Of all the spinal fusion surgeries performed, 46% were for lumbar fusion, 42% were for cervical fusion and the remaining 13% were for thoracic or multi-level fusion procedures. This rise in number of spinal fusion surgeries has created the demand for bone graft substitutes and has consequently boosted the overall growth of this industry. In addition, rise in the incidence of arthritis, increase in geriatric population and increase in obesity rate has triggered the growth of this market. Technological advancements, growing demand for minimally invasive procedures and rising patient awareness are the other factors that has considerably augmented the growth of this market. The global orthobiologics market was valued at USD 3,754.6 million in 2012 and is expected to grow at a CAGR of 5.9%from 2013 to 2019 to reach at an estimated value of USD 5,519.9 million in 2019.

At present, viscosupplementation accounts for the largest share of the orthobiologics market. The growth in this market is attributed to growing popularity of knee treatments and its ability to act as an effective pain killer as compared to NSAIDS and others. This market is followed by bone morphogenetic proteins (BMPs) which is characterized by its ability to provide faster recovery, lesser pain and ability to stimulate patients own cells for regeneration. However, the market is expected to show a negative growth rateduring the forecast period due to decline in the sales of “INFUSE” a Medtronic product. Severe side effects associated with INFUSE due to its heavy off label usage led to recall of this product by the U.S FDA. Synthetic bone substitutes and stem cell based products are expected to witness a significant growth during the forecast period. The growth of these segments is witnessed due to reduced cost, quick recovery and eliminated risk of disease transmission.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1747

Geographically, North America and Europe dominates the orthobiologics market. The dominance in these region is witnessed due to rise in incidence of arthritis and higher obesity rates that has surged the demand for minimally invasive procedures such as bone grafting and growth factor treatment. These treatments offer enhanced well-being and durability, with minimal side effects while eliminating the need for repeated hospital visits. However, the Asia-Pacific region is expected to show highest growth rate during the forecast period. The demand for orthobiologics in this region is witnessed due to increase in number of orthopedic disease due to change in lifestyle, change in diet which all lead to increasing obesity rate and consequently leads to arthritis and other bone disorders. Moreover, rise in geriatric population and increase in sports related injuries are other factors likely to drive the growth of orthobiologics in this region.

The major players engaged in the orthobiologics market include Medtronic, Inc., DePuySynthes, Wright Medical Technology, Inc., Stryker Corporation, Orthofix, Inc., NuVasive, Inc., and other significant players.

Global Orthobiologics Market to Rise at 5.90% CAGR from 2013 to 2019

Transparency Market Research (TMR), a market intelligence company, throws light on the overall market for orthobiologics and answers a series of questions covering all the key attributes related to the orthobiologics market.

Q. What factors will drive the growth of the orthobiologics market in the coming years? Which is the prime factor amongst them?

The prime factor fuelling the growth of the market is the increasing count of certain limitations associated with the usage of allografts and autografts. The key concerns related with the usage of allografts is the increasing risk of disease transmission and the decline in the availability of allografts. On the other hand, though autografts are the gold standard for carrying out orthopedic procedures, there are major drawbacks of using autografts such as the additional surgery involved and donor site morbidity. Hence, to overcome these disadvantages of allografts and autografts, bone graft substitutes are being utilized for performing orthopedic surgeries, hence boosting the growth of the orthobiologics market.

In addition, the rising count of sports injuries, the increasing count of orthopedic surgeries, and the increasing demand for cutting-edge products are also some of the key factors propelling the growth of the market for orthobiologics. Furthermore, the rising geriatric population and the increasing occurrence of chronic arthritis globally will also driver the growth of the market.

Q. Which is the most common orthobiologic treatment utilized and why? What are the top application areas of orthobiologics technology?

The most common orthobiologic treatment utilized is platelet-rich plasma (PRP) therapy. This therapy is a holistic approach utilized for speeding up the healing and regeneration of tendon, muscular injuries, and ligament, and lowering the time of recovery. This method has been utilized since the 1990s for assisting the healing of spinal injuries and facilitating recovery post a plastic surgery. This therapy garnered international attention in 2008 when it was utilized for the treatment of Tiger Woods, an American professional golfer and one of the highest paid athletes in the world, during his rehabilitation after micro-fracture surgery.

The key application areas of orthobiologics technology are reconstructive surgery, trauma, and spinal fusion. Amongst these, the segment of spinal fusion led the market in 2013 due to the rising count of spinal fusion surgeries, increasing occurrence of arthritis, the increasing demand for minimally invasive procedures, and the rising occurrence of obesity globally.

Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1747

Q. What is the latest innovation in orthobiologics technology?

There are several innovative products and treatments that will steer the market toward a healthy future. But one that stands out is a new magnesium-based bone void filler product, named OsteoCrete™, slated to be launched by Bone Solutions Inc. (BCI) by October 2016. This product will be utilized for long-bone as well as orthopedic applications and has been approved by the FDA. OsteoCrete™ is easily assimilated back in the body, is resorbable, moldable, non-toxic, and osteoconductive in nature. It will be utilized to overcome the deficiencies found in commonly-utilized calcium-based bone void fillers as well as cements which may result in low surgery success rates.